Pacira BioSciences reports 6% revenue growth in Q2 2026, closes iovera° divestiture with Zimmer Biomet.

Pacira BioSciences announced a 6% year-over-year revenue increase to $192.4 million in Q2 2026, driven by growth in its non-opioid pain therapies EXPAREL and ZILRETTA. The company completed the divestiture of its iovera° business to Zimmer Biomet, receiving $73.6 million upfront and potential future payments. Pacira is advancing its gene therapy candidate PCRX-201 for knee osteoarthritis and expanded reimbursement for EXPAREL by UnitedHealthcare, enhancing market access. The company updated its 2026 revenue guidance to $735-$760 million, reflecting the iovera° sale, and remains focused on innovation and long-term growth.